
For patients with advanced driver gene-negative non-small cell lung cancer (NSCLC), current first-line standard treatment primarily relies on immunotherapy alone or immunotherapy combined with chemotherapy. However, long-term patient outcomes still need to be further improved. Antibody-drug conjugates (ADCs) targeting trophoblast cell-surface antigen 2 (TROP2), through their dual mechanisms of cytotoxicity and immune activation, may enhance the effects of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade.
At the 2026 European Society for Medical Oncology (ESMO) Congress, data were presented from a multicenter Phase II study led by Professor Zhang Li and Professor Shaodong Hong’s team at Sun Yat-sen University Cancer Center, evaluating BAT8008 in combination with BAT1308, an anti-PD-1 monoclonal antibody, as first-line treatment for advanced NSCLC. During the congress, Oncology Frontier invited Professor Shaodong Hong for an exclusive interview. Drawing on BAT8008’s distinctive design and mechanism of action, as well as the newly reported Phase II clinical data, he discussed the clinical positioning and future development of TROP2 ADC–immunotherapy combinations in advanced NSCLC.
Oncology Frontier:
Considering BAT8008’s mechanism of action and the results of this study, what differentiates BAT8008 from other TROP2 ADCs? How does BAT8008 combined with immunotherapy perform in terms of efficacy and safety as first-line treatment for advanced NSCLC?
Professor Shaodong Hong: BAT8008 is a novel antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2). Its mechanism of action involves a TROP2-targeting monoclonal antibody conjugated to a cytotoxic payload through a linker. BAT8008 uses a topoisomerase I inhibitor as its payload. Its key differentiating design feature is a drug-to-antibody ratio (DAR) of approximately 6. The fundamental aim of this design is to maximize the balance between antitumor activity and safety, thereby achieving a wider therapeutic window.
First-line treatment generally involves a relatively long treatment course, placing high demands on patient tolerability. In a comparable study, EVOKE-03/KEYNOTE D46, the combination failed to achieve the desired progression-free survival (PFS) benefit in patients with high PD-L1 expression, and there was also no statistically significant difference in overall survival (OS). The prevailing academic view is that this may be related to tolerability challenges resulting from adverse events.
By contrast, Phase II data on BAT8008 combined with BAT1308 showed that the overall patient population had good tolerability. Although common adverse events associated with ADCs include anemia and decreased white blood cell counts, the incidence of grade 3 or higher anemia and white blood cell count decreases in this study was no more than 20% for either event. The overall proportion of patients discontinuing treatment due to adverse events was also below 6%. While achieving a high objective response rate (ORR), this combination regimen also demonstrated favorable bone marrow safety, offering an effective and well-tolerated treatment option for patients with driver gene-negative disease in the first-line setting.
Oncology Frontier:
Based on the subgroup data from this study, could you discuss differences in the benefits of BAT8008-based combination therapy across different histological types and PD-L1 expression levels? What implications do these findings have for the precise selection of patients who are most likely to benefit?
Professor Shaodong Hong: Biomarker exploration for TROP2 ADCs is currently a major research focus in lung cancer. Several previous studies have demonstrated that TROP2 protein expression levels themselves are not directly associated with ADC efficacy. An increasing body of data suggests that internalization efficiency is the key factor influencing ADC efficacy. Our team is currently evaluating the membrane-to-cytoplasm ratio of TROP2 as a measure of drug internalization efficiency, with the aim of identifying more precise predictive biomarkers.
This study enrolled previously untreated patients with driver gene-negative NSCLC. Since the treatment consisted of an ADC combined with a programmed cell death protein 1 (PD-1) monoclonal antibody, biomarkers previously established in immunotherapy remain relevant. The data showed a clear stepwise increase in patient benefit with increasing PD-L1 expression: the ORR was approximately 47.2% in patients with PD-L1-negative disease (tumor proportion score [TPS] <1%), 58.6% in those with low PD-L1 expression (TPS 1%–49%), and as high as 83.3% in those with high PD-L1 expression (TPS ≥50%).
In addition, when analyzed by histological subtype, patients with non-squamous NSCLC appeared to derive greater benefit from this combination regimen. Subgroup data showed an ORR of 65.2% in patients with non-squamous disease, with median PFS (mPFS) not yet reached; among patients with squamous disease, the mPFS was 7.72 months. These early signals suggest that future confirmatory Phase III studies should place particular emphasis on stratification by PD-L1 expression and histological type, and that non-squamous NSCLC may be a key focus for further development of ADC–immunotherapy combinations. Whether the deep responses observed in the short term will ultimately translate into long-term OS benefit remains to be determined through more mature follow-up data.
Oncology Frontier:
Considering the current development of drugs targeting the same target, how do you assess the potential positioning of this combination strategy in the future first-line treatment landscape for driver gene-negative NSCLC? What are the plans for further research?
Professor Shaodong Hong: Two Phase III studies of TROP2 ADCs combined with immunotherapy have reported publicly available data. The first evaluated sacituzumab tirumotecan combined with pembrolizumab versus pembrolizumab alone. It demonstrated a significant PFS improvement in Chinese patients with NSCLC and PD-L1 TPS ≥1%, although the OS data are not yet mature. The other study evaluated sacituzumab govitecan combined with pembrolizumab versus pembrolizumab monotherapy. The results were negative, with no clear PFS benefit and completely overlapping OS curves.
These findings suggest that when TROP2 ADC–immunotherapy combinations are directly compared with standard immunotherapy alone in patients with high PD-L1 expression, or with immunotherapy plus chemotherapy in the overall population, their efficacy may be associated with differences in the molecular design, efficacy, and tolerability of individual ADCs. We still need to accumulate more early efficacy signals before advancing these combination regimens into the first-line treatment setting. The current results—one positive and one negative—indicate that this is not a combination that is guaranteed to succeed.
Furthermore, the control arms in both Phase III studies mentioned above received immunotherapy alone. As we know, for patients with PD-L1-negative disease and even those with high PD-L1 expression, platinum-based chemotherapy combined with immunotherapy is currently the preferred treatment approach. One key question that had not yet been answered for sacituzumab tirumotecan plus pembrolizumab was whether, in patients with PD-L1-negative disease, a TROP2 ADC combined with immunotherapy would necessarily be superior to platinum-based chemotherapy combined with immunotherapy.
The data from the OptiTROP-Lung06 study, presented by Professor Caicun Zhou at this year’s ESMO Congress, have provided an initial answer. This is the world’s first Phase III study to directly compare a TROP2 ADC plus immunotherapy with platinum-based chemotherapy plus immunotherapy specifically in patients with PD-L1-negative disease and to achieve a positive PFS result. These findings not only validate the potential of TROP2 ADCs in first-line chemotherapy-free strategies but also offer a highly promising new treatment option for this difficult-to-treat patient population.
Overall, TROP2 ADCs combined with immunotherapy have the potential to reshape the first-line treatment landscape for driver gene-negative NSCLC. However, different TROP2 ADCs have distinct efficacy and safety profiles. Their clinical positioning and value must therefore be rigorously evaluated within the context of current first-line standard treatment for NSCLC.
Oncology Frontier:
Given the possibility of overlapping toxicity profiles between ADCs and immunotherapy, how do you think a multidisciplinary system for adverse event prevention and management should be established in real-world first-line clinical practice to ensure that patients can continue treatment?
Professor Shaodong Hong: ADCs are cytotoxic agents, whereas immunotherapy consists of immunomodulatory agents. Their overall toxicity profiles do not overlap substantially, but clinicians must pay close attention to adverse events affecting specific organ systems.
The first concern is ADC-related myelosuppression. The extent of ADC-related myelotoxicity depends on the potency of the payload and the stability of the linker. In clinical practice, proactive complete blood count monitoring is necessary to detect decreased white blood cell counts, neutropenia, and anemia.
The second concern is on-target toxicity. Typical on-target toxicities associated with TROP2 ADCs include oral mucositis and ocular surface toxicity. Preventive measures should be implemented to manage these events at grades 1–2.
In addition, the most important adverse event to monitor, and one that may overlap with immunotherapy-related toxicity, is interstitial lung disease (ILD). Although the mechanisms underlying ADC-induced and immunotherapy-induced ILD differ, the management principles are similar: early identification, prompt treatment discontinuation, and timely intervention with corticosteroids according to the severity grade. When the two treatments are combined, differential diagnosis of ILD represents a major clinical challenge. In the future, more refined classification may be possible with the help of artificial intelligence (AI)-based radiomics.
It is important to remain vigilant because ADC-related ILD often progresses more rapidly than ILD caused by immunotherapy alone. It can also result in more severe permanent lung damage that is more difficult to reverse. Fortunately, the BAT8008 combination regimen reported in this study had a relatively low incidence of ILD and other pulmonary disorders, which is closely related to ongoing improvements in ADC manufacturing processes and design.
Oncology Frontier:
Considering the advances reported at this year’s ESMO Congress, which research developments or emerging topics in innovative lung cancer drug development are of greatest interest to you?
Professor Shaodong Hong: This year’s ESMO Congress presented several major studies with the potential to change clinical practice. Taken together, they reflect an increasingly diversified development landscape shaped by novel therapeutic modalities, including ADCs, T-cell engagers (TCEs), and multispecific antibodies.
In the field of driver gene-negative NSCLC, the OptiTROP-Lung06 study attracted considerable attention. It is the world’s first Phase III study of a TROP2 ADC combined with immunotherapy versus platinum-based chemotherapy combined with immunotherapy to achieve a positive PFS result in patients with PD-L1-negative disease.
In EGFR-mutant disease with tyrosine kinase inhibitor (TKI) resistance, the congress continued to highlight two major research directions. The first is precision intervention guided by resistance mechanisms, exemplified by Phase III data on dual-target blockade in patients with MET amplification or overexpression. The second is treatment strategies that are independent of specific resistance mechanisms, with a major focus on ADCs. One notable development was the first positive Phase III data worldwide comparing an EGFR/HER3 bispecific ADC with chemotherapy. In addition, updated OS data comparing sacituzumab tirumotecan with chemotherapy may further establish ADCs as a new standard treatment option following TKI resistance.
Meanwhile, in small cell lung cancer (SCLC), T-cell engagers (TCEs), such as DLL3/CD3 bispecific antibodies, achieved positive results for both PFS and OS in first-line maintenance treatment for extensive-stage SCLC, demonstrating substantial clinical potential.
Across these studies, the central theme is the development of innovative drugs and the iterative advancement of therapies with different mechanisms of action. One clear trend is that, after establishing their role in later-line treatment, these novel agents are progressively moving into earlier disease settings, including first-line treatment for advanced disease, consolidation therapy for locally advanced disease, and even neoadjuvant treatment. The results of this series of Phase III clinical studies are continuously reshaping clinical treatment pathways for NSCLC.
However, moving treatment strategies into earlier settings depends heavily on precise patient selection and meticulous management throughout the entire treatment course. At the same time, the emergence of new therapies brings a range of novel clinical challenges, including comprehensive toxicity management, deeper investigation of resistance mechanisms, and effective strategies to overcome newly acquired resistance. For patients with both driver gene-positive and driver gene-negative NSCLC, addressing these challenges will be among the key priorities of the next generation of clinical research.
